by Marisa Wexler, MS | Feb 26, 2026 | Myeloma News
An “immuno-gene” therapy that turns a virus into a cancer-fighting agent has received a fast-track designation from the U.S. Food and Drug Administration (FDA). The experimental treatment, known as SRN-101, is being developed for recurrent high-grade glioma, an...
by MM360 Staff | Feb 26, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Marisa Wexler, MS | Feb 25, 2026 | Myeloma News
People in the U.S. with certain gynecological cancers that are resistant to first-line chemotherapies now have a new treatment option: The U.S. Food and Drug Administration (FDA) has approved the use of the immune-modulating therapies Keytruda (pembrolizumab) and...
by MM360 Staff | Feb 25, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Marisa Wexler, MS | Feb 24, 2026 | Myeloma News
The U.S. Food and Drug Administration (FDA) is reviewing an application from Bristol Myers Squibb (BMS) seeking approval of its investigational oral therapy iberdomide for the treatment of people with hard-to-manage multiple myeloma. The application seeks approval of...
